Sign In
Buy AIM
$0.732
-0.0947 (-11.46%)
At Close: Jun 03, 2026
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM)
04:05pm, Friday, 04'th Apr 2025
NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common s
Electric Guitar shares resume trading on AIM as company reboots with new board and cash shell strategy
02:56am, Wednesday, 02'nd Apr 2025
Electric Guitar PLC (AIM:ELEG) is back on the market. The company's shares will resume trading on AIM Tuesday morning following a major board shake-up and the completion of a fundraising round that s
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript
09:19am, Tuesday, 01'st Apr 2025
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference
Aimia Inc. (AIMFF) Q4 2024 Earnings Call Transcript
11:39am, Friday, 28'th Mar 2025
Aimia Inc. (OTCPK:AIMFF) Q4 2024 Results Conference Call March 28, 2025 8:30 AM ET Company Participants Joe Racanelli - Vice President of Investor Relations Tom Finke - Executive Chairman Rhys Summert
Deposed AIM royalty ASOS enjoys a rare week in the sun
02:01am, Saturday, 22'nd Mar 2025
Once royalty of the AIM market, with a valuation that once put it on the cusp of the FTSE 100, ASOS PLC's (LSE:ASC)fall from grace has been rapid—and well documented. Earlier this week, its shares w
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
08:45am, Tuesday, 11'th Mar 2025
On-demand video webcast now available
Jersey Oil and Gas investors to watch keenly as UK Govt's fiscal consultations proceed
07:41am, Friday, 07'th Mar 2025
Details will need to be fleshed out, but the UK government has heard the concerns of the North Sea industry, that's what Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) boss Andrew Benitz told investors
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
01:20pm, Wednesday, 26'th Feb 2025
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “America
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director
08:30am, Wednesday, 26'th Feb 2025
OCALA, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Company's Board of Directors (the “Board”) has, b
Several subjects who received the highest dose in Phase 1 will also be included in Phase 2 Several subjects who received the highest dose in Phase 1 will also be included in Phase 2
AIM ImmunoTech Releases Virtual Investor “What This Means Segment”
08:45am, Tuesday, 11'th Feb 2025
Tom Equels, CEO of AIM ImmunoTech and Professor Casper H.J. van Eijck, MD, PhD, Pancreato-biliary Surgeon at Erasmus MC, discuss the Phase 1b/2 clinical trial involving AIM's Ampligen® (rintatolimod)
OCALA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will not proceed with an offering pursuant to its Regi
Planned Investigational New Drug application to expand on previous clinical work at the University of Alabama-Birmingham in which administration of Ampligen as an intranasal adjuvant increased immune
KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight
03:35am, Tuesday, 04'th Feb 2025
KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said
